Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 31.32 USD 4.26% Market Closed
Market Cap: 628.6m USD
Have any thoughts about
Simulations Plus Inc?
Write Note

Simulations Plus Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Simulations Plus Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Interest Income Expense
$4.6m
CAGR 3-Years
144%
CAGR 5-Years
N/A
CAGR 10-Years
52%
Veeva Systems Inc
NYSE:VEEV
Interest Income Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inspire Medical Systems Inc
NYSE:INSP
Interest Income Expense
$23.4m
CAGR 3-Years
N/A
CAGR 5-Years
73%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Interest Income Expense
$21.3m
CAGR 3-Years
314%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Interest Income Expense
$18.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Waystar Holding Corp
NASDAQ:WAY
Interest Income Expense
-$205.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
628m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
20.55 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Simulations Plus Inc's Interest Income Expense?
Interest Income Expense
4.6m USD

Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Interest Income Expense amounts to 4.6m USD.

What is Simulations Plus Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
52%

Over the last year, the Interest Income Expense growth was 27%. The average annual Interest Income Expense growth rates for Simulations Plus Inc have been 144% over the past three years , and 52% over the past ten years .

Back to Top